CKD Bio Q3 Revenue Falls 14% Year on Year

Bitget2026/10/30 05:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

CKD Bio’s third-quarter 2026 operating loss widened 308.6% year over year to 5.99 billion won.
Revenue fell 14% year over year to 29.33 billion won.
Net loss widened 381% year over year to 10.48 billion won.
First-nine-month operating results swung to a 12.7 billion won loss from a 3.5 billion won profit a year earlier.
Revenue for that period declined 5.7% year over year to 111.11 billion won.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CKD Bio Corporation published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030800591), on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

CKD Bio Q3 Revenue Falls 14% Year on Year

You may also like

Crypto prices